MARÍA PILAR
GARCÍA ALFONSO
Profesora asociada de Ciencias de la Salud
ROCÍO
GARCÍA CARBONERO
Profesora asociada de Ciencias de la Salud
Publicaciones en las que colabora con ROCÍO GARCÍA CARBONERO (23)
2023
-
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
The Lancet, Vol. 402, Núm. 10395, pp. 41-53
-
Health-related quality of life (HRQoL) associated with fruquintinib in the global phase 3, placebo-controlled, double-blind FRESCO-2 study.
Journal of Clinical Oncology
-
Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 2, pp. 379-388
2022
2021
2020
-
Comprehensive Characterization of the Mutational Landscape in Localized Anal Squamous Cell Carcinoma
Translational Oncology, Vol. 13, Núm. 7
-
FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: The randomised phase III VISNÚ-1 trial
ESMO Open, Vol. 5, Núm. 6
-
Update of the recommendations for the determination of biomarkers in colorectal carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology
Clinical and Translational Oncology, Vol. 22, Núm. 11, pp. 1976-1991
2019
-
Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study
Annals of Oncology, Vol. 30, Núm. 1, pp. 124-131
-
Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy
Annals of Oncology, Vol. 30, Núm. 3, pp. 439-446
2018
2017
-
Exposure–response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial
Cancer Chemotherapy and Pharmacology, Vol. 80, Núm. 3, pp. 599-608
2016
-
Is neutropenia a prognostic or a predictive factor for second line metastatic colorectal cancer (mCRC) patients (Pts)? Exploratory analysis from RAISE, a randomized, double-blind, phase III study of ramucirumab (RAM) + FOLFIRI vs placebo (PBO) + FOLFIRI
Annals of Oncology, Vol. 27, pp. vi198
-
Is regorafenib providing clinically meaningful benefits to pretreated patients with metastatic colorectal cancer?
Clinical and Translational Oncology, Vol. 18, Núm. 11, pp. 1072-1081
-
Subgroup analysis in RAISE: A randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression
Annals of Oncology, Vol. 27, Núm. 11, pp. 2082-2089
2015
-
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): A randomised, double-blind, multicentre, phase 3 study
The Lancet Oncology, Vol. 16, Núm. 5, pp. 499-508
-
SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015
Clinical and Translational Oncology, Vol. 17, Núm. 12, pp. 972-981
-
Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Clinical and Translational Oncology, Vol. 17, Núm. 4, pp. 264-273
2014
-
Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer
Clinical and Translational Oncology, Vol. 16, Núm. 11, pp. 942-953
2012
-
Guidelines for biomarker testing in colorectal carcinoma (CRC): A national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM)
Clinical and Translational Oncology, Vol. 14, Núm. 10, pp. 726-739